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Abstract Mass spectrometry (MS)-based label-free proteo-
mics offers an unbiased approach to screen biomarkers related
to disease progression and therapy-resistance of breast cancer
on the global scale. However, multi-step sample preparation
can introduce large variation in generated data, while inappro-
priate statistical methods will lead to false positive hits. All
these issues have hampered the identification of reliable pro-
tein markers. A workflow, which integrates reproducible and
robust sample preparation and data handling methods, is high-
ly desirable in clinical proteomics investigations. Here we
describe a label-free tissue proteomics pipeline, which encom-
passes laser capture microdissection (LCM) followed by nano-
scale liquid chromatography and high resolution MS. This
pipeline routinely identifies on average ∼10,000 peptides
corresponding to ∼1,800 proteins from sub-microgram
amounts of protein extracted from ∼4,000 LCM breast cancer
epithelial cells. Highly reproducible abundance data were gen-
erated from different technical and biological replicates. As a
proof-of-principle, comparative proteome analysis was per-
formed on estrogen receptor α positive or negative (ER+/−)
samples, and commonly known differentially expressed pro-
teins related to ER expression in breast cancer were identified.
Therefore, we show that our tissue proteomics pipeline is
robust and applicable for the identification of breast cancer
specific protein markers.
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LTQ-Orbitrap-XL Linear ion trap/Orbitrap mass
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Introduction
With the rapid development of high resolution mass spec-
trometry (MS), global screening of protein markers becomes
feasible and is starting to play an important role in biomark-
er discovery [1]. Protein markers are more related to disease
phenotype and are more targetable for therapy in compari-
son with transcriptome-based biomarkers. Hence, identifi-
cation of sensitive and specific protein makers is of
importance for clinical practice. However, to develop a
reproducible workflow for the robust identification of such
biomarkers, several important technical aspects have to be
taken into account.
A challenge in reliable protein marker identification
is the heterogeneity of tumor tissues. Tumor cells are
almost always surrounded by stromal compartments and
infiltrating cells and the percentage of epithelial tumor
cells can vary dramatically between individual tumor
samples. Laser capture microdissection (LCM) is a
widely applied technique to isolate tumor cells from
their surrounding tissues [2, 3], which allows enrich-
ment of cells of interest and removes bias introduced
by comparison of tumor samples with different mor-
phology. Nevertheless, LCM is a laborious and time-
consuming procedure, which means that only limited
number of cells can be collected from individual sam-
ples, and is therefore difficult to apply on large cohort
of tumor tissues when a large number of tumor cells per
sample are needed for a successful measurement. Fur-
thermore, a highly sensitive proteomics platform is required to
analyze proteome of LCM materials in depth. Nanoscale
liquid chromatography coupled to tandem mass spectrometry
(nLC-MS/MS) enables identification of >1,000 proteins from
sub-microgram breast cancer tissue in a 3 h gradient, and
makes it possible to apply LCM for large scale biomarker
discovery [4].
Secondly, the human proteome exhibits a very large
dynamic range in protein expression, while MS based anal-
ysis can cover at best up to 4–5 orders of magnitude. This
directly leads to reduced reproducibility for measurements
of lower abundant proteins, because their corresponding
peptides will not be consistently observed through all mea-
sured MS datasets, even though these peptides are
biologically present through all the experimental samples,
which leads to a large percentage of missing data in MS
based proteomics. Moreover, sample handling steps are
often complicated and need to be carefully controlled [5].
Furthermore, label-free quantification (LFQ) is often used
for global screening of biomarkers but the quantitative ca-
pacity of LFQ remains a question. All these obstacles make
it difficult to identify clinically valuable protein markers
using an MS based proteomics approach. Great efforts have
been made to improve protocols for sample preparation
[6–8], to create sensitive and confident methods for multiple
peak alignment, protein quantification and database search-
ing [9, 10], and to perform more robust and reliable statistical
analyses [11–14], in order to reliably identify biomarkers.
Taken together, a well-designed pipeline for proteomics based
biomarker discovery can greatly improve reproducibility of
sample preparation, produce more quantitative data, and there-
fore increase the possibility of identifying reliable and clini-
cally relevant biomarkers.
Here we describe a robust label-free tissue proteo-
mics pipeline that is applicable for breast cancer bio-
marker discovery. This pipeline identified on average
∼10,000 peptides corresponding to ∼1,800 proteins
from as little as ∼4,000 LCM breast cancer epithelial
cells (corresponding to sub-microgram protein lysates).
Obtained data were highly reproducible and quantita-
tive, and allowed identification of more than 100 dif-
ferentially expressed proteins between estrogen receptor
α positive (ER+) and negative (ER−) breast tumor
samples.
Methods
Tumor Tissues and Samples
Ten fresh frozen tumor tissues were selected from our
liquid N2 bank, of which 5 were ER positive (ER+) and
5 were ER negative (ER−). ER and progesterone recep-
tor (PR) status of 10 samples were determined by
enzyme-linked immunosorbent assay. From one ER tu-
mor sample, five laser capture microdissected control
samples (LCM-CTRLs, biological replicates) were pre-
pared using a previously described protocol [5, 7]. From
the same biological source, whole tissue lysate (WTL)
was prepared and measured by nLC-MS/MS for 12
times (whole tissue lysate control samples, WTL-CTRLs,
technical replicates). The remaining five ER+ and four ER−
samples were used as experimental samples to identify differ-
entially expressed proteins. Detailed sampling plan and ex-
perimental design is explained in Supplementary Fig. 1. This
study was approved by the Medical Ethics Committee of the
Erasmus Medical Center Rotterdam, The Netherlands (MEC
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02.953) and was performed in accordance to the Code of
Conduct of the Federation of Medical Scientific Societies in
the Netherlands.
Isolation of Breast Tumor Epithelial Cells
Cryosectioning and LCM were performed according to pre-
viously described protocol [7]:
1. Sterilize and hydrate polyethylene naphthalate (PEN)
coated glass slide (Carl Zeiss MicroImaging, GmbH,
Munich, Germany) under ultraviolet light for 30 min;
2. Cut 4 to 6 8-μm tissue cryosections and attach those
sections on a PEN slide;
3. Fix tissue sections in ice-cold 70 % ethanol, briefly dry
slides for 30 s at room temperature, and then dehydrate
in ice-cold 100 % ethanol;
4. Dry PEN slide in room temperature and place it in
a plastic slide container wrapped with aluminum
foil or Parafilm and store the slide container at
−80 °C;
5. Prior to LCM, defrost the PEN slide at room temperate
for 5 min inside a sealed slide container;
6. Rinse the PEN slide in tap water for 15 s, stain
tissue sections in hematoxylin for 30 s, blue staining
in tap water for 15 s, and finally dehydrate tissue
sections in 50, 70, 95 and 100 % ethanol for 15 s
each and 60 s for the final 100 % ethanol wash. A
volume of 200 μl Halt protease and phosphatase
inhibitor cocktail (100 × concentration, Thermo
Fischer Scientific Inc., Rockford, IL, USA) is added
into 20 ml of tap water, 50 and 70 % ethanol,
respectively;
7. Isolate tumor cells using a P.A.L.M. MicroBeam
system, and collect ∼500,000 μm2 (equivalent to
∼4,000 tumor cells [8]) in ZEISS opaque adhesive
caps (Carl Zeiss MicroImaging, GmbH, Munich,
Germany);
8. Suspend captured cells in 20 μl of 0.1 % RapiGest
surfactant (Waters Corp., Milford, MA, USA) in
50 mM ammonium bicarbonate (SIGMA, Saint Louis,
MO, USA) buffer, store sample at −80 °C.
Tip: (1) An optimal range of tumor area per dissec-
tion is between 5,000 and 25,000 μm2 to ensure suc-
cessful catapulting; (2) Always check the entire tumor
sections under the microscope at 5× magnification to
ensure all LCM tumor pieces are collected in the adhe-
sive cap; (3) After transferring captured tumor cells into
a LoBind Eppendorf tube (Eppendorf, Hamburg, Ger-
many), check the cap under microscope to ensure all
LCM tumor cells are transferred into the LoBind Eppen-
dorf tube.
In-Solution Tryptic Digestion
In-solution tryptic digestion was performed according to the
instructions of the manufacturer and as previously described
[5]:
1. Lyse cell suspension in 0.1 % RapiGest buffer using an
Ultrasonics Disruptor Sonifier II (Model W-250/W-450,
Branson Ultrasonics, Danbury, CT) at 70 % amplitude
for 1 min;
2. Denature proteins at 95 °C for 5 min;
3. Reduce denatured proteins at 60 °C for 30 min by add-
ing dithiothreitol (SIGMA, Saint Louis, MO, USA) to a
final concentration of 5 mM;
4. Alkylate reduced proteins in the dark for 30 min by
adding iodoacetamide (Thermo Scientific, Rockford,
IL, USA) to a final concentration of 15 mM;
5. Digest unfolded proteins at 37 °C for 4 h using MS-
grade porcine modified trypsin gold (Promega, Madi-
son, WI, USA) at a 1:4 (enzyme/protein) ratio (∼400 ng
of protein can be extracted from ∼4,000 microdissected
cells [1], therefore 100 ng of trypsin was used for
digestion);
6. Acidify tryptic digests with 0.5 % trifluoroacetic acid
(SIGMA, Saint Louis, MO, USA) and incubate mixture
at 37 °C for 30 min to terminate tryptic digestion and
degrade RapiGest;
7. Centrifuge digests at 14,000 rpm for 15 min at 4 °C to
precipitate undissolved cellular debris and the insoluble
fraction of hydrolyzed RapiGest;
8. Transfer supernatant into high performance liquid chro-
matography vials for nLC-MS/MS measurements.
nLC-MS/MS Analysis
Proteomic profiling was performed on an Ultimate 3000
nLC system (Dionex, Amsterdam, The Netherlands)
connected online with a hybrid linear ion trap/Orbitrap mass
spectrometer (LTQ-Orbitrap-XL, ThermoElectron, Bremen,
Germany) following a slightly modified procedure as de-
scribed previously [8].
1. Method of sample loading: A volume of 20 μl
(equivalent to ∼4,000 cells or ∼400 ng) from each
sample was loaded on a trap column (PepMap C18,
300 μm I.D. × 5 mm, 5 μm particle size, 100 Å
pore size; Dionex, Amsterdam, The Netherlands) for
concentration and desalting using 0.1 % trifluoro-
acetic acid (in water) as loading solvent at a flow
rate of 20 μl/min;
2. nLC systems and elution gradient: After sample load-
ing, the trap column was switched online to directly
connect with a reversed-phase 75-μm I.D. × 50-cm
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fused silica capillary column packed with 3-μm C18
particles (PepMap, Dionex, Amsterdam, The Nether-
lands). Peptides were gradually eluted out at a flow rate
of 250 nl/min at 40 °C column temperature using the
following binary gradient: the gradient started with
100 % mobile phase A (97.9 % H2O, 2 % acetonitrile,
0.1 % formic acid) to 25 % mobile phase B (80 %
acetonitrile, 19.02 % H2O, 0.08 % formic acid) over
the first 120 min, and then a steeper gradient was used
to further increase mobile phase B to 50 % in the next
60 min;
3. MS systems and settings: The eluted peptides were
directly sprayed with a voltage of 1.6 kV into the
on-line coupled LTQ-Orbitrap-XL MS using nano
electro-spray ionization source equipped with a
metal-coated nano-scale emitter (New Objective,
Woburn, MA). Mass spectra were acquired over a
mass-to-charge ratio (m/z) range 400–1,800 Th at a
resolving power of 30,000 at 400 m/z. Target of
automatic gain control (AGC) was set at 106 ions
and lock mass set to 445.120025 m/z (protonated
(Si(CH3)2O))6) [15]. On the basis of this full scan,
the top 5 intensive ions were consecutively isolated
(AGC target set to 104 ions) and fragmented by
collisionally activated dissociation applying 35 %
normalized collision energy in the linear ion trap.
Parent ions within a mass window of ±5 ppm were
then excluded for MS/MS fragmentation for the next
3 min or until the precursor intensity fell below a
signal-to-noise ratio of 1.5 for more than 10 scans
(early expiration). Orbitrap full scan spectra and ion
trap MS/MS fragmentation spectra were acquired
partially simultaneously (preview mode for FTMS
master scan enabled).
Database Searching
The recorded MS spectra were analyzed by MaxQuant
Software (version 1.1.1.36) [9].
1. Database searching and identification: The initial
search was limited to a mass window of 7 ppm
and a fragment mass window of 0.5 Th. To con-
struct an MS/MS peak list file, up to top 8 peaks
per 100 Da window were extracted and submitted to
search against a concatenated forward and reverse
version of the UniProtKB/Swiss-Prot human data-
base (generated from version 2011_03, human tax-
onomy, 20,287 entries). Carbamidomethylation of
cysteines was defined as fixed modification, while
protein N-terminal acetylation and methionine oxi-
dation were defined as variable modifications for
database searching. Also, an option of second
identifications was selected to allow identification
of co-eluting peptides with second highest searching
score from a subset of MS/MS spectra. The cutoff
of false discovery rate (FDR) for peptide and pro-
tein identification was set to 0.01, and only peptides
with ≥7 amino acid residues were allowed for iden-
tification. In addition, at least one unique peptide
was required to identify a protein;
2. Protein quantification and multiple peak alignment:
LFQ was performed by MaxQuant software on iden-
tified razor and unique peptides in order to properly
quantify identified proteins. Razor peptides are non-
unique peptides assigned to the protein group iden-
tified by most other peptides [16], which follows
“occam’s razor” principle. Detailed methodology of
LFQ algorithm was previously described in [17].
The “match between the runs” option was chosen
to match the same accurate masses between multiple
nLC-MS/MS runs within a retention time window of
2 min.
Data Processing and Statistical Analysis
Data processing after MaxQuant data analysis was divided
into two parts and performed as follows. A flow chart
summarizes the complete strategy of statistical analyses
used in our data handling pipeline (Supplementary Fig. 2).
1. Log2 transformation, normalization and filtering of the
data:
1.1. Peptide abundances given in the “peptides.txt”
file generated by MaxQuant were first Log2 trans-
formed and then median peptide abundances in
individual samples were centered;
1.2. Protein abundances normalized by LFQ algo-
rithm integrated in MaxQuant were Log2 trans-
formed for further analyses. Label free
algorithm takes the maximum number of iden-
tified peptides between any two samples and
compares the intensity of these peptides to
determine peptide ratios. Protein abundance is
computed using median values of all peptide
ratios of certain protein [17];
1.3. Peptides reserved for further analysis adhered to
following criteria: (a) peptides were unique to one
protein group, (b) sequences were not recognized
as reversed sequences of all peptides in the data-
base, and (c) peptides with large percentage of
missing data were excluded from mixed-effect
analysis of variance (ME-ANOVA) analysis. Due
to the small sample cohort in this study, only
peptides with abundance data in at least 5
158 J Mammary Gland Biol Neoplasia (2012) 17:155–164
(50 %) observations out of 9 samples were includ-
ed in the ME-ANOVA analysis. In case of larger
sample cohorts (e.g. n>60), the threshold for pep-
tide inclusion could be set to a minimum of 30 %
observations;
2. Statistical analysis:
In this part of data handling, we took two sepa-
rate statistical approaches. Both of the two
approaches were composed of pre-selection step
(more sensitive, but less stringent) and refinement
step (less sensitive, but more stringent). The pre-
selection steps were used to find proteins that show
a trend in differential expression between two ex-
perimental groups and therefore reduced numbers of
multiple testing occurring in the refinement steps.
The refinement steps aided to discover the strongest
putative markers in the discovery study. The first
approach consisted of ME-ANOVA pre-selection
and t-test refinement (Step 2.1–2.3), which enabled
finding proteins that were expressed in most of
experimental samples but had significantly different
abundance levels between two experimental groups.
Therefore we defined this difference as “abundance”
difference. The second approach combined Fisher’s
exact test for pre-selection and t-test refinement
(Step 2.4). It aimed to identify proteins preferential-
ly expressed in one of the experimental groups but
which were not necessarily detected in majority of
the experimental samples, which was defined as
“presence-absence” difference. However, low abun-
dant proteins are often not reproducibly detected
through the entire MS dataset due to undersampling
issue of shotgun proteomics, even though these pro-
teins are indeed present in all the samples. There-
fore, some stably expressed low abundant species
can be mistaken for putative markers only when
presence and absence are taken into account instead
of actual abundance of these proteins. To avoid high
FDR, only the proteins that were also differentially
expressed at the level of imputed protein abundan-
ces were regarded as putative candidates.
2.1. ME-ANOVA test was performed on filtered
peptides from Step 1.3, according to a previ-
ously described method [12, 13, 18]. This
model takes into account four types of bias
that may be introduced during the experimen-
tal procedure, known as experimental, group,
peptide, and random error, and tries to cali-
brate these biases to achieve maximal separa-
tion between different experimental groups. In
this model, higher abundant peptides assigned
to certain protein weigh more than their lower
abundant counterparts in estimating protein
abundance. In our study, maximum 10 most
abundant peptides per protein were used to
test significance of their assigned proteins us-
ing a robust linear regression model in ME-
ANOVA. However, it is difficult to estimate
different biological and technical variations
between the clinical samples since those sam-
ples were not collected under experimental
conditions, especially no technical replicate
was used for nLC-MS/MS profiling. Therefore,
this model is only suitable for pre-selection of
putative markers, and an additional step of
consolidation is required to find truly differentially
expressed proteins between different experimental
groups;
2.2. Type I error (false positive hits) introduced
during multiple hypothesis testing was cor-
rected for using Benjamini-Hochberg p-value
adjustment [19]. In this way, differentially
expressed proteins were found using a cor-
rected p-value cutoff of 0.05;
2.3. Next to the ME-ANOVA test, an additional t-test
was performed on pre-selected putative markers
identified by ME-ANOVA using their protein
abundances to further refine the putative protein
candidates (p<0.05, permutation-based FDR0
0.05);
2.4. In ME-ANOVA test and subsequently t-test,
proteins present in only one of the experimen-
tal groups led to invalid test and therefore
could not be captured. Therefore, a Fisher’s
exact test was performed on MS/MS counts
of all identified proteins except those recog-
nized as reversed sequence (p<0.05). In this
way, proteins present in (mainly) one of the
experimental groups could be discovered. Fur-
thermore, data imputation was performed on
the abundance of these differentially expressed
proteins to replace missing values by normal
distribution, and a t-test was performed on the
imputed abundances to confirm differentially
expressed patterns of these proteins (p<0.05,
permutation-based FDR00.05);
2.5. Hierarchical clustering was performed on the
abundance of differentially expressed proteins.
For hierarchical clustering analysis, protein ex-
pression data were first centered based on their
median abundances, followed by clustering both
samples and proteins using Euclidean distance
and complete linkage.
Note: The filtering steps were performed in
Microsoft Excel 2010. DanteR (version 1.0.1.1)
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and Perseus (version 1.2.0.17) were used to per-
form different types of statistical analysis includ-
ing Log2 transformation, correlation plot,
statistical tests, imputation, p-value adjustment,
and volcano plot, while hierarchical clustering
was executed using Cluster 3.0 and visualized in
TreeView (version 1.1.5r2-win).
Results and discussion
In this study, we describe a robust tissue proteomics pipeline
for biomarker discovery, which enables identification of ER
associated proteins in human breast cancer. The entire pipe-
line is divided into two different stages. The first stage
consists of all procedures that generate raw nLC-MS/MS
profiling data, while the latter part includes both upstream
(multiple peak alignment, peptide and protein identification,
and quantification) and downstream (statistical analysis)
data handling steps. A flow chart summarizes the basic
structure of this pipeline (Fig. 1).
To evaluate reproducibility of our tissue proteomics
pipeline, we first inspected the number of identified
peptides and protein groups of different samples. On
average, 10,792±275 (x±s), 10,539±742 and 10,374±
491 peptides were identified corresponding to 1,869±40,
1,776±98 and 1,869±60 protein groups in 12 WTL-
CTRLs, 5 LCM-CTRLs and 9 experimental samples,
respectively, and identifications of razor and unique
peptides in three types of samples were also roughly
equivalent (Table 1). Furthermore, as expected, LCM-
CTRLs had larger coefficient of variations (CVs) (7.0,
7.3, and 7.4 %) than WTL-CTRLs (2.6, 2.6, and 2.6 %)
on peptide, razor peptide and unique peptide identifica-
tions, respectively (Table 1). Thus, our tissue proteomics
pipeline was able to consistently identify similar numb-
ers of peptides and proteins in the same type of tissue
materials. Peptide identifications and their abundances in
all the samples are listed in Supplementary table 1 and
2, and protein identifications and their abundances in all
samples are listed in Supplementary table 3 and 4.
Reproducibility of abundance data was first investi-
gated through Pearson correlation of all LCM-CTRLs
and WTL-CTRLs using their peptide abundances. On
average, correlation between LCM-CTRLs was 0.91±
0.02 (x±s), and a slightly higher correlation was ob-
served between WTL-CTRLs (0.97±0.01) (Fig. 2a, left
panel). This indicates a good reproducibility of our
sample preparation protocol and nLC-MS/MS analyses.
Correlation of peptide abundances between different ex-
perimental samples was lower (0.72±0.04) (data not
shown), which can be explained by both technical var-
iation (e.g.: different tissue quality and different mor-
phology) and, more importantly, biological variation
(e.g.: inter- and intra-tumor heterogeneity). Next, we
inspected reliability of estimated protein abundance.
An average higher correlation was observed between
all LCM-CTRLs (0.94±0.01) and WTL-CTRLs (0.98±
0.01) using LFQ protein abundances (Fig. 2a, right
panel) compared to correlation of peptide abundances.
Moreover, we also observed a good Pearson correlation
between protein abundance and MS/MS counts of the
same sample in both LCM-CTRL (0.84±0.03) and
WTL-CTRL (0.81±0.02) (data not shown). Thus, the
LFQ algorithm properly computed and normalized pro-
tein abundance.
Frozen tumor tissues
Cryosection (8 µm sections)
Microdissection (4,000 cells)
In-solution tryptic digestion (4h)
nLC-MS/MS profiling (3h gradient)
Data Generation
Multi-alignment (MaxQuant)
Normalization (MaxQuant & DanteR)
Statistical test (DanteR & Perseus)
Protein quantification (MaxQuant)
Multivariate analysis (DanteR 
Perseus & Cluster 3.0)
Data Analysis
Figure 1 Flowchart
summarizes the principle of
label-free tissue proteomics
pipeline. This technical plat-
form is divided into two stages.
The first stage generates nLC-
MS/MS raw data from tumor
tissues, and the second part
proposes a general data pro-
cessing procedure used in MS-
based label-free proteomics
biomarker discovery study
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Quality of our data generation workflow was further
inspected through reproducibility of peptide identifica-
tions in WTL-CTRLs, LCM-CTRLs or experimental
samples. Peptide identifications in ≤33 %, 34–66 %,
and ≥67 % and of all samples were considered to be
of low, medium or high reproducibility, respectively. In
WTL-CTRLs, LCM-CTRLs, and experimental samples
80 %, 73 %, and 59 % of peptides were identified with
high reproducibility, whereas 9 %, 14 %, and 23 % of
peptides were identified with medium reproducibility,
and 11 %, 13 %, and 18 % with low reproducibility,
respectively (Supplementary Fig. 3a, upper panel). At
the protein level, 85 %, 80 %, and 73 % of identifica-
tions was observed in more that 66 % of the samples
(Supplementary Fig. 3a, lower panel). Furthermore, we
observed that average CVs of the peptide abundances of
WTL-CTRLs, LCM-CTRLs and experimental samples
were 32.5 %±12.5 %, 64.1 %±24.8 % and 64.3 %±
32.8 %, respectively (Supplementary Fig. 3b). Surpris-
ingly, there was no significant difference in CVs of
peptide abundances between LCM-CTRLs and experi-
mental samples (P>0.05), whereas there was a signifi-
cant difference at the LFQ protein level (33.3 %±
25.3 % and 81.3±51.5 %, respectively, P<0.000) (Sup-
plementary Fig. 3b). In addition, CVs of WTL-CTRLs
and LCM-CTRLs were overall lower in LFQ protein
data (21.1 %±19.9 % and 33.3 %±25.3 %, respectively)
than peptide data (32.5 %±12.5 % and 64.1 %±24.8 %,
respectively), while CVs of experimental samples be-
came larger after normalizing peptide abundance into
protein abundance (64.3 %±32.8 % and 81.3±51.5 %)
(Supplementary Fig. 3b). These data indicate that the
raw peptide abundance was properly normalized before
further data mining, and further supports that LFQ al-
gorithm properly normalized protein abundance. In con-
clusion, these observations suggest that reproducible
data were generated using our tissue proteomics plat-
form, and that upstream data analysis produced high
quality data for further statistical analyses.
Next, WTL-CTRLs and LCM-CTRLs were compared
to investigate the overlap in identified proteins. In total
we identified 2,265 protein groups in 12 WTL-CTRLs
and 5 LCM-CTRLs, of which 1,853 (81.8 %) were
identified in both sample types (Fig. 2b). Only 241
(10.6 %) and 171 (7.5 %) protein groups were exclu-
sively identified in either WTL-CTRLs or LCM-CTRLs,
respectively (Fig. 2b). Unique proteins that were typi-
cally identified in WTL included most of major histo-
compatibility Class II molecules. These antigens are
exclusively located on immune cells such as antigen-
presenting cells and lymphocytes, which are only rarely
Peptide abundance
WTL-CTRL LCM-CTRL
LFQ protein intensity
WTL-CTRL LCM-CTRL
Correlation coefficient 
0.55 0.60 0.65 0.70 0.75 0.80 0.85 0.90 0.950.50
a
1853
(81.8%)
241
(10.6%)
171
(7.5%)WTL-CTRL LCM-CTRL
b
Figure 2 Application of label-free tissue proteomics pipeline to con-
trol and experimental breast cancer samples. a Pearson correlation of
peptide and protein abundance between WTL-CTRLs and LCM-
CTRLs; b AVenn diagram reveals shared and unique identified protein
groups in WTL-CTRLs (green circle) and LCM-CTRLs (red circle)
Table 1 Average numbers of identified peptides and protein groups
Category WTL-CTRL samples LCM-CTRL samples Experimental samples
Total peptides 10,792±275a (2.6 %)b 10,539±742 (7.0 %) 10,374±491 (4.7 %)
Razor peptides 488±10 (2.0 %) 534±29 (5.4 %) 483±17 (3.5 %)
Unique peptides 9,664±254 (2.6 %) 9,263±684 (7.4 %) 9,217±472 (5.1 %)
Protein groups 1,869±40 (2.1 %) 1,776±98 (5.5 %) 1,869±60 (3.2 %)
aMean±Standard deviation (x±s);
b Percentages in brackets represent coefficient of variations of numbers of peptide and protein identification.
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microdissected along with tumor cells and thus not
often identified in LCM samples. Furthermore, extracel-
lular matrix proteins such as some collagens present in
the stromal compartment were identified in WTL sam-
ples. Some of these proteins are highly abundant and
may have caused undersampling during the MS profil-
ing, meaning that their lower abundant co-elutes in
WTL samples escaped MS/MS fragmentation and
remained unidentified, explaining 7.5 % unique protein
identification in LCM-CTRLs samples.
As a proof-of-principle, we applied the tissue proteomics
and data handling pipeline to an experimental set of 5 ER+
and 4 ER− breast cancer tissues with the aim of identifying
some known ER associated protein markers, in order to
show that this platform can be used for large scale of
biomarker discovery study. Protein abundance of ER (Entry
name: ESR1_HUMAN), and downstream regulated proteins
PR (Entry name: PRGR_HUMAN), Cadherin-1 (Entry
name: CDH1_HUMAN) and Annexin A1 (Entry name:
ANXA1_HUMAN), were investigated. As expected, ER
and PR were completely absent in all 4 ER− samples
(Fig. 3, upper panel), in concordance with in-house available
enzyme-linked immunosorbent assay data from the same
samples. Also, Cadherin-1 and Annexin A1 were elevated in
ER+ and ER− samples (Fig. 3, lower panel), respectively.
Cadherin-1, also known as E-cadherin, is well-known to me-
diate cell–cell adhesion, is important in breast cancer suppres-
sion, and is frequently down-regulated in ER− breast cancer
cells [20]. Several clinical studies also showed that loss and
aberrant expression of Cadherin-1 more frequently occurs in
ER− breast cancer cases [21, 22], especially of the triple
negative phenotype [23]. Also, Annexin A1 expression has
been associated with breast cancer cell lines of the basal
subtype [24], which are all ER−. In conclusion, these data
indicate that the LFQ algorithm from MaxQuant was able to
correctly determine relative protein abundance between dif-
ferent groups of breast cancer samples.
In order to reveal differentially expressed proteins
between ER+ and ER− breast tumors, two different
comparative proteome analyses were performed: (1) re-
vealing quantitative differences (ME-ANOVA with t-test
refinement); and (2) revealing proteins more frequently
expressed in one of the experimental arms compared to
the other (Fisher’s exact test with t-test refinement).
Using ME-ANOVA test, a total of 435 differentially
expressed proteins were found between ER+ and ER−
breast cancer samples (p<0.05). ER+ and ER− samples
were well separated into two clusters using these 435 protein
markers (Fig. 4a, left panel). However, the protein dendro-
gram (vertical axis) did not nicely fall into two clusters,
indicating some low discriminatory proteins were also
included in this clustering. To further refine the analysis
to find the strongest markers, a t-test was used on Log2
intensity values of 435 proteins to confirm differences
between ER+ and ER− samples. With this more strin-
gent refinement, 165 proteins were confirmed as differ-
entially expressed proteins between ER+ and ER−
samples (p<0.05, permutation-based FDR00.05) (Sup-
plementary table 5). Those 165 proteins formed a more
solid protein dendrogram with two major arms (Fig. 4a,
right panel). These findings suggest that ME-ANOVA
with t-test refinement can reliably identify differentially
expressed proteins between ER+ and ER− breast cancer
samples.
Figure 3 Four breast cancer
related proteins and their
expression in ER+ and ER−
breast cancer samples
162 J Mammary Gland Biol Neoplasia (2012) 17:155–164
Additionally to reveal proteins more frequently present in
one of the experimental arms, MS/MS counts of all identi-
fied proteins were subsequently analyzed by a Fisher’s exact
test in order to identify protein markers that are mainly
present in one of the experimental groups. In total, 102
differentially expressed proteins were discovered using this
approach. We further consolidated 63 proteins by
performing a t-test on imputed Log2 intensity of these 102
proteins using a p-value cutoff of 0.05 and permutation-
based FDR of 0.05 (Supplementary table 6). ER+ and
ER− samples could also be correctly classified using these
63 proteins (Fig. 4b). As expected, we found that ER and PR
were enriched in ER+ breast cancer samples. Also, carbonic
anhydrase 12 (Entry name: CAH12_HUMAN) and Protein
S100-A9 (Entry name: S10A9_HUMAN) were augmented
in ER+ and ER− breast cancer samples, respectively
(Fig. 4b). Carbonic anhydrase 12 was documented as an
ER regulated protein in breast cancer, and expression level of
this protein is highly positively correlated to expression level
of ER [25, 26]. Protein S100-A9 has been associated with
basal breast cancer which are typically ER− [27]. Moreover,
31 out of 63 differentially expressed proteins were also iden-
tified by ME-ANOVA test with t-test refinement with the
same direction of regulation in ER+ and ER− samples (Sup-
plementary table 7), which demonstrates validity of two types
of statistical approaches, but both methods also provided
complementary advantages in discovering putative markers.
Therefore, ER, PR and some other ER associated proteins
a ME-ANOVA test
ER+ ER-
T-test refinement
ER+ ER-
3.00
2.00
1.00
0.00
1.00
2.00
3.00
b
ESR1_HUMAN
PRGR_HUMAN
S10A9_HUMAN
ER+ ER-
CAH12_HUMAN
3.00
2.00
1.00
0.00
1.00
2.00
3.00
ER+ ER-
Fisher’s exact test with T-test refinement
Figure 4 Differentially
expressed proteins were
discovered by different
statistical analyses. a
Hierarchical clustering
separates ER+ and ER−
samples using 435 (left panel)
and 165 (right panel)
differentially expressed proteins
found by ME-ANOVA and re-
fined using t-test; b Hierarchi-
cal clustering of 63
differentially expressed proteins
between ER+ and ER− samples
which were discovered using
Fisher’s exact test with t-test
refinement, as well as expres-
sion of 4 differentially
expressed proteins out of these
63 proteins
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were only identified using combination of Fisher’s exact test
and imputation-based t-test refinement, indicating this ap-
proach is of added value to the quantitative statistical analysis.
In summary, we described a highly reproducible and
robust label-free tissue proteomics pipeline for MS-
based biomarker discovery. This platform produced
high-quality MS data from as little as ∼4,000 LCM
breast tumor epithelial cells and reliably quantified pro-
tein abundance from observed peptide abundance. More
importantly, it allowed identification of a large number
of differentially expressed proteins between different
experimental groups under investigation with relatively
low FDR. Some of these differentially expressed pro-
teins were previously described in literature as markers
for ER+ or ER− breast cancer. Therefore, we conclude
that this label-free tissue proteomics pipeline is suitable
for clinical biomarker discovery.
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